Continued Access to Elranatamab for Patients With Multiple Myeloma
Gives continued elranatamab treatment to people with multiple myeloma from earlier trials.
Plain-language title generated from the registry record
Registry title: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Key facts
- Where
- Kyoto and Shibuya-ku, JapanSee the 2 sites
- Phase
- Phase 4
Where in Japan
- University Hospital Kyoto Prefectural University of MedicineKyoto, JapanTaking people
- Japanese Red Cross Medical CenterShibuya-ku, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06057402EU 2023-505200-33-00
- Record updated
- 1 July 2026
- Original description
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.Read full original descriptionShow less
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Inclusion: Participants must agree to follow the reproductive criteria as outlined in the protocol; Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Exclusion: Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study; Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.